These results conclusively demonstrate that Bcan-Ntrk1 is a bona fide glioma driver and show that in vivo somatic chromosomal engineering can be used to model oncogenic chromosomal rearrangements in the mouse brain. This evidence concerns the gene NTRK1 and glioma.